Oxford BioDynamics (LON:OBD) Stock Price Down 11.6% – What’s Next?

Oxford BioDynamics Plc (LON:OBD)’s stock price was down 11.6% during trading on Wednesday . The stock traded as low as GBX 0.94 ($0.01) and last traded at GBX 0.97 ($0.01). Approximately 4,693,215 shares traded hands during mid-day trading, an increase of 14% from the average daily volume of 4,110,961 shares. The stock had previously closed at GBX 1.10 ($0.01).

Oxford BioDynamics Stock Down 0.2 %

The company’s fifty day simple moving average is GBX 1.25 and its 200 day simple moving average is GBX 3.95. The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22. The firm has a market capitalization of £3.11 million, a PE ratio of -16.63 and a beta of 0.42.

Insider Buying and Selling

In related news, insider David Holbrook bought 49,653 shares of the company’s stock in a transaction on Monday, October 28th. The shares were acquired at an average cost of GBX 1 ($0.01) per share, with a total value of £496.53 ($606.26). 16.78% of the stock is owned by insiders.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.